The pharmacokinetics of cefmenoxime were determined after a 30-min intravenous infusion of 15 mg/kg of total body weight to 33 adult subjects with normal renal function (CLCR, >80 ml/min per 1.73 i2, group I), mild renal insufficiency (CLCR, 40 to 79 ml/min per 1.73 m2, group II), moderate renal insufficiency (CLCR, 10 to 39 ml/min per 1.73 m2, group lII), or severe renal impairment (CLCR, <10 mI/min per 1.73 mi2, group IV) or to patients between hemodialysis (CLCR, <10 ml/min per 1.73 mi2, group V). Concentrations of cefmenoxime in serum and urine were determined by high-pressure liquid chromatography, and serum concentrations were fit to a two-compartment model. There was no significant relationship between creatinine clearance and either peak serum concentrations or volume of distribution at steady state. Patients in group I excreted 81% of the dose into the urine within 24 h; recovery decreased with worsening renal function. The mean terminal half-lives in groups I to V were 1.06, 1.50, 3.55, 4.60, and 11.4 h, respectively. There were good linear relationships between creatinine clearance, and the elimination rate and total body clearance of cefmenoxime. Dosage recommendations for subjects with renal insufficiency are proposed.
MATERIALS AND METHODS Subjects. Thirty-three adult subjects gave informed consent and were divided into five groups (Table 1) based on glomerular filtration rate as determined by a 24-h endogenous creatinitie clearance.
None of the subjects were infected at the time of study. Patients with renal insufficiency were recruited from the service of the Division of Nephrology by one of us (D.S.), and all nondialysis subjects had a stable serum creatinine at the time of study. Before drug administration, all subjects had a limited physical exam, and laboratory studies were performed for blood chemistry and hematology. Subjects were excluded if they had a known history of allergy to cephalosporins or a type I hypersensitivity to penicillins, were pregnant or nursing, had received antibiotics within the previous 2 weeks, or had severe hepatic or cardiovascular disease.
* Corresponding author.
Procedures. (i) Drug administration. Cefmenoxime was supplied as 500-mg vials of dry powder (manufactured by Takeda Chemical Industries Ltd.) and was reconstituted and diluted in 50 ml of 5% glucose solution immediately before administration. All subjects received 15 mg of cefmenoxime per kg of total body weight as a monitored 30-min intravehous infusion.
Blood samples were obtained just before administration and, for groups I to IV, at the following times after the end of the infusion: 0 (end of infusion), 0.25, 0.5, 1.0, 4.0, 8.0, 12.0, and 24.0 h. Subjects receiving routine maintenance hemodialysis (group V) were administered cefmenoxime as above, beginning ca. 2.5 h before the start of a dialysis session which routinely lasted 4 h. A blood sample was obtained at the end of the infusion and at the following times after completion of dialysis: 1, 2, 4, 8, 16, and 24 h. Urine was collected in all subjects producing urine from 0 to 2, 2 to 8, and 8 to 24 h after initiation of the infusion. After measurement of the volume, samples were taken from each voiding for cefmenoxime assay. All samples were immediately centrifuged and frozen at -40°C before assay. A creatinine clearance was calculated after pooling all urine and determining the urinary creatinine cencentration (Technicon Autoanalyzer). Cefmenoxime, at concentrations measured in this study, was found not to interfere with creatinine values determined by the Technicon (SMAC) system.
(ii) Analytical methods. Serum and urine samples were assayed by the high-pressure liquid chromatography methodology of Noonan et al. (8) . The sample containing cefmenoxime was deproteinated with acetonitrile (Fisher highpressure liquid chromatography grade) containing the internal standard, p-anisic acid (Aldrich Chemical Co.). The supernatant was poured into a glass tube and mixed for 10 s. Then the tube was centrifuged at 2,000 rpm for 5 min. The supernatant was poured into centrifuge tubes, and the acetonitril was evaporated in a Vortex evaporator for 20 min at 30°C and refrigerated. Just before injection, 100 lu'l of the mobile phase (15% [vol/vol] variation of 3.6% (n = 34). A plasma control that was spiked at 0.5 ,ug/ml had a mean analysis of 0.53 ,ug/ml (106%) and a coefficient of variation of 6.6% (n = 13). The lowest concentrations of cefmenoxime measurable in plasma were 0.3 p,g/ ml for groups I to IV and 5 ,ug/ml for group V. For urine, the lowest measurable concentration was S ,ug/ml. Pharmacokinetic analysis. (i) Groups I to IV. Concentration-time data were graphically analyzed to obtain initial parameter estimates. Graphical analysis indicated that plasma samples could be fit adequately by using a biexponential equation (i.e., a two-compartment open model). Computer analysis was performed with NONLIN programmed with the two-compartment model postinfusion equation, with coefficients R and S and exponents a and e as parameters (6) . Coefficients A and B were calculated by the equations of Gibaldi and Perrier (3). The micro rate constants, renal and total body clearances of cefmenoxime, area under the curve, central volume of distribution, and volume of distribution at steady state for each subject were calculated from NONLIN parameter estimates by conventional methods. All fits were done with weights of 1 for the individual subjects, producing coefficients of variation of >0.95. Weights of lly and 1/y2 did not improve the fit and, in some patients with renal insufficiency, generated estimates of the terminal half-life which were thought to be inappropriately long due to excessive weighting of very low serum concentrations.
(ii) Group V. Estimates of the postdialysis elimination rates were obtained by linear regression of the postdialysis serum concentrations.
For all 33 subjects, the statistical relationships of creatinine clearance to the elimination rate (13), and peak blood concentration for cefmenoxime, were calculated by linear regression. Linear regression was also used for the nondialysis subjects (n = 23) to determine the relationship of creatinine clearance to total body clearance, area under the curve, and volume of distribution at steady state. The relationship between half-life and creatinine clearance was estimated from the NLIN regression program of the statistical analysis service (SAS Institute, Cary, N.C.).
RESULTS
All subjects completed the study, and there were no untoward effects. Results are summarized in Tables 1, 2, and   3 .
Subjects with normal renal function. The mean peak concentration at the termination of the infusion was 87.2 ± 14.3 ,ug/ml. The mean elimination half-life was 1.06 + 0.36 h. The mean central and steady-state volumes of distribution were 6.56 ± 1.8 and 11.3 + 2.3 liters per 1.73 m2, respectively. The mean total body clearance and renal clearance were 197 + 27 and 146 ± 65 ml/min per 1.73 m2, respectively. Of the dose administered, an average of 81.1 + 11.1% was recovered as the parent compound over 24 h.
Subjects with impaired renal function. As renal function Aeclined, mean half-life increased to 1.50, 3.55, 4.60, and 11.4 h in groups II to V, respectively (Table 2 ). There was no significant relationship between peak serum concentration and creatinine clearance (peak concentration, -0.0635(CLCR) + 13.4; r2, 0.09). There were significant linear relationships between creatinine clearance and the elimination rate (Fig. 1) and between total body clearance and creatinine clearance (total body clearance, 1.49(CLCR) + 20.2; r2, 0.87; P, <0.05). There was a significant nonlinear relationship between the terminal half-life (T112) and creatinine clearance given by the equation: (T112) (hours) = 58.2/ (CLCR + 4.2).
As renal function declined, renal clearance declined, as did the total amount of drug recovered in urine over 24 h (Tables 2 and 3) .
Mean urine concentrations remained above the MIC for susceptible organisms for all three collection periods; only three subjects from group I did not have measurable concentrations during the 8-to 24-h collection period. DISCUSSION The results of our study are consistent with previous reports in which the pharmacokinetics of cefmenoxime in normal volunteers (4, 10) and patients with renal insufficiency (5) were examined (D. P. Alexander, J. G. Gambertoglio, S. L. Berriere, and J. E. Conte. Abstract, Clin. Pharmacol. Ther. 33:234, 1983). Granneman et al. reported a mean cefmenoxime half-life of 0.91 h and a mean plasma clearance of 245 ml/min and recovered 75% of the dose in urine from 15 normal subjects (4). Similar results were found by Sennello et al., who reported a mean half-life of 1.14 h and recovered 55% of the dose from 10 normal subjects (10) . The lack of complete urinary recovery has been reported for other cephalosporins excreted primarily by the kidneys (7) . Although cefmenoxime is detectable in bile (11), additional mechanisms, including in vivo degradation in bladder urine, are likely responsible for the remainder of the unrecovered dose. The total body clearance of cefmenoxime is greater than creatinine clearance, consistent with previous observations that renal tubular secretion provides a major route for renal elimination (10) . Because of its relatively short halflife, a 4-to 6-h dosing interval for most serious systemic infections would appear appropriate, and accumulation would be minimal.
Significant relationships exist between creatinine clearance and the half life, elimination rate (,B), and total body clearance of cefmenoxime. Each of these relationships has been used for similar drugs to develop dosage nomograms. Since renal impairment has no significant effect upon either the volume of distribution at steady state or the maximum serum concentration, the relationship between creatinine clearance and the half-life provides a simple mechanism for arriving at an appropriate dosage. The half-life for cefmenoxime was similar for all subjects with a creatinine clearance over 40 ml/min, and dosage adjustments are not recommended for these patients. Administration of maintenance doses approximately every third half-life, thereby allowing for elimination of ca. 90% of body stores, would prevent significant accumulation and avoid prolonged periods of subtherapeutic serum concentrations. In this manner and using the equation relating the terminal half-life to creatinine clearance, dosages for cefmenoxime in patients with normal and impaired renal function are proposed (Table 4) .
Guidelines for dosage modifications of antibiotics in subjects with renal insufficiency are usually arrived at from studies similar to ours. However, it is important to note that the safety of an antibiotic after multiple doses cannot be adequately assessed from a single-dose study. Thus it is recommended that patients with substantial renal insufficiency receiving reduced doses be monitored closely, ideally with the aid of serum concentration determinations, until safety can be demonstrated.
